9.52
0.00 (0.00%)
| 前收盘价格 | 9.52 |
| 收盘价格 | 9.17 |
| 成交量 | 50,880 |
| 平均成交量 (3个月) | 36,163 |
| 市值 | 417,844,256 |
| 市盈率 (P/E TTM) | 63.47 |
| 价格/销量 (P/S) | 48.28 |
| 股市价格/股市净资产 (P/B) | 13.91 |
| 52周波幅 |
| 营业毛利率 | 28.99% |
| 营业利益率 (TTM) | -68.64% |
| 稀释每股收益 (EPS TTM) | 0.050 |
| 季度收入增长率 (YOY) | -36.10% |
| 季度盈利增长率 (YOY) | 136.50% |
| 流动比率 (MRQ) | 10.71 |
| 营业现金流 (OCF TTM) | 2.08 M |
| 杠杆自由现金流 (LFCF TTM) | 1.27 M |
| 资产报酬率 (ROA TTM) | 7.18% |
| 股东权益报酬率 (ROE TTM) | 14.83% |
市场趋势
| 短期 | 中期 | ||
| 行业 | Medical Instruments & Supplies (US) | 混合的 | 混合的 |
| Medical Instruments & Supplies (全球的) | 看涨 | 混合的 | |
| 股票 | Anbio Biotechnology | - | - |
AIStockmoo 评分
| 分析师共识 | 0.0 |
| 内部交易活动 | NA |
| 价格波动 | 4.5 |
| 技术平均移动指标 | 2.5 |
| 技术振荡指标 | -2.5 |
| 平均 | 1.13 |
|
Anbio Biotechnology is a medical device company focused on in vitro diagnostics. The company's mission is to change the diagnostics market by personalizing and decentralizing the current diagnostic solutions for faster diagnosis to improve patient prognosis. The company proposes this by providing accessible and affordable diagnostic solutions globally at the forefront of science and offering laboratory, wellness, at-home, and point-of-care (POCT) in vitro diagnostic (IVD) solutions. The business planning is to focus on validating and commercializing the existing portfolio of in vitro diagnostic products, as well as generating additional data required to support regulatory submissions and compliance, including under frameworks such as the In Vitro Diagnostic Regulation (IVDR). |
|
| 部门 | Healthcare |
| 行业 | Medical Instruments & Supplies |
| 投资方式 | Small Growth |
| 内部持股比例 | 4.78% |
| 机构持股比例 | 4.94% |
该时间范围内无数据。
该时间范围内无数据。
支撑、阻力和趋势线水平是由人工智能(AI)模型生成的,请谨慎解读。
投资组合